ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: 2385 • ACR Convergence 2024

    Increased Type I Interferon Inducible Genes Expression in the Peripheral Blood of Patients Presenting Cutaneous Lupus Erythematosus Manifestations

    Anastasia- Bilio Chronopoulou1, Maria Gerochristou2, Sylvia Raftopoulou3, Alexander Stratigos4 and Clio Mavragani5, 1National and Kapodistrian University of Athens, Athens, Greece, 2Andreas Syggros Hospital, National and Kapodistrian University of Athens, Athens, Greece, 3Molecular and Applied Physiology Unit, Department of Physiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece, 41st Department of Dermatology-Venereology, Faculty of Medicine, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece, 5Department of Physiology and Pathophysiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece

    Background/Purpose: Cutaneous Lupus Erythematosus (CLE) is a chronic autoimmune skin disease characterized by a spectrum of cutaneous manifestations resulting from immune dysregulation and inflammation. While…
  • Abstract Number: 2530 • ACR Convergence 2024

    Single-cell Multi-omics Analysis of Reactive Lymph Nodes, Affected Tissues, and Blood Reveals a Naive-like CD4+TRAIL+ T Cell Population That Differentially Directs Effector Anti-nuclear Antigen Reactive Responses in Patients with Sjogren’s Syndrome and Systemic Sclerosis

    Theodoros Ioannis Papadimitriou1, Prashant Singh2, Arjan van Caam3, Madelon Vonk4, Irene E. van der Horst-Bruinsma5, Peter van der kraan3, Erik Aarntzen6, Martijn Huijnen7, Hans Koenen8 and Rogier Thurlings1, 1Radboudumc, Department of Rheumatology, Nijmegen, Gelderland, Netherlands, 2Radboudumc, Department of Medical BioSciences, Nijmegen, Netherlands, 3Radboudumc, Department of Rheumatology, Nijmegen, Netherlands, 4Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 5Department of Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, 6Radboudumc, Department of Medical Imaging, Nijmegen, Netherlands, 7Radboudumc, Department of Medical BioSciences, Nijmegen, Gelderland, Netherlands, 8Radboudumc, Department of Medical Immunology, Nijmegen, Gelderland, Netherlands

    Background/Purpose: Recognition of self-peptides by autoreactive CD4+ T-cells is central to the disruption of immune tolerance. Although systemic autoimmune diseases such as Sjogren’s syndrome (SjS)…
  • Abstract Number: 2661 • ACR Convergence 2024

    Changes in Krebs Von Den Lungen 6 Levels (∆KL6) Predict Fibrosing Progression of Interstitial Lung Disease in Patients with an Underlying Connective Tissue Disease (CTD-ILD)

    Fredeswinda Romero-Bueno1, María Carmen Vegas-Sánchez2, lydia Abasolo Alcazar3, Mª Jesus Rodriguez Nieto2, Cristina Vadillo-Font4, M Asuncion Nieto5, Laura Cebrián6, Belén López-Muñiz6, Jesus Loarce Martos7, Juan Rigual8, hildegarda Godoy Tundidor9, Rosalía Laporta10, Irene Llorente-Cubas11, Gema Bonilla12, Luis Gomez Carrera13, Rosario García-Vicuña14, Ana Jaureguizar7, Jose Luis Morell Hita7, Claudia Valenzuela15 and Olga Sánchez-Pernaute16, and the NEREA Study group for Autoimmune ILD, 1Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, 2Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, 3IdISSC. HCSC, Madrid, Spain, 4Hospital Clinico S Carlos, Madrid, Spain, 5Hospital Clínico San Carlos, Madrid, Madrid, Spain, 6Hospital Universitario Infanta Leonor, Madrid, Spain, 7Hospital Universitario Ramón y Cajal - IRYCIS, Madrid, Spain, 8Ramón y Cajal University Hospital, Madrid, Madrid, Spain, 9Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Madrid, Spain, 10Hospital Universitario Puerta de Hierro, Madrid, Spain, 11Hospital Universitario de La Princesa, Madrid, Spain, 12H. Universitario La Paz, Madrid, Spain, 13Hospital Universitario La Paz, Madrid, Spain, 14Hospital Universitario de la Princesa, Madrid, Madrid, Spain, 15Hospital Universitario La Princesa, Madrid, Spain, 16Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain

    Background/Purpose: Krebs von den Lungen-6 (KL6) is a mucin-1 glycoprotein produced by type 2 alveolar epithelial cells , which increase at peripheral blood show a…
  • Abstract Number: 0002 • ACR Convergence 2024

    Preclinical Evaluation of BCMA And/or CD19 Nanobody-based Single or Compound CAR-T Cells Targeting B and Plasma Cells Associated with Autoimmune Disorders

    Byeong Hyeok Choi1, Vincent M DeStefano2, Masayuki Wada2, Kevin G Pinz1, Greg Deener2, Nabil Hagag1, Ahmed Abdel-Razek1, Yu Ma3, Jing Luo3 and Yupo Ma2, 1iCell Gene Therapeutics Inc., Stony Brook, NY, 2iCell Gene Therapeutics, Inc., Stony Brook, NY, 3iCar Bio Therapeutics Ltd, Zhongshan City, Guangdong, China (People's Republic)

    Background/Purpose: CD19 single and BCMA-CD19 compound chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable activity against autoimmune disorders, although relapses with CD19 CAR…
  • Abstract Number: 0087 • ACR Convergence 2024

    SYNCAR: An Engineered IL-2/IL-2R-system That Selectively Enhances CD19 CAR T Cells to Deplete B Cells and Provide Therapeutic Benefit in SLE and RA Mouse Models Without Lymphodepletion

    Ethan Jung1, Marie semana1, Ivan Cheng1, Helena Silva1, Sandro Vivona1, Somya Singh1, Michele Bauer1, Mohammed Ali1, Henry Rosas1, Woei Chang1, Deepti Rokkam1, Patrick Lupardus1, Martin Oft1 and Paul-Joseph Aspuria2, 1Synthekine, Menlo Park, 2Sythekine, Menlo Park, CA

    Background/Purpose: CD19 CAR-T therapy has demonstrated efficacy in autoimmune (AI) diseases like systemic lupus erythematosus (SLE) and lupus nephritis (LN), showing its potential beyond oncology.…
  • Abstract Number: 0244 • ACR Convergence 2024

    Adjunctive Belimumab Exerts Favorable Ferritin Recovery and Survival for Post-COVID Interstitial Lung Disease in Patients with Immune Mediated Inflammatory Diseases Treated with Rituximab: A Case Series

    Pei-Hsinq Lai1, Cheng-Hsun Lu2 and Song-Chou Hsieh3, 1Taipei City Hospital, Taipei, Taiwan (Republic of China), 2National Taiwan University Hospital, Taipei, Taiwan, 3National Taiwan University Hospital, Taipei, Taiwan (Republic of China)

    Background/Purpose: Post-COVID interstitial lung disease (post-COVID ILD) is a critical sequelae yet the role of immunomodulatory therapies remains unclear. We explored to characterize post-COVID ILD…
  • Abstract Number: 0309 • ACR Convergence 2024

    Characteristics and Factors Associated with Treatment Response Among Patients with Eosinophilic Fasciitis: A Systematic Review and Meta-analysis

    Omar Hamdan1, Roa'a Alshajrawi1, Qais Mussa1, Yazeed Alajlouni1, Yazan Dabbah1, Rawan Fratekh1, Yousef Al-Mabrouk2, Shatha Al-Mabrok2 and Ahmad A. Toubasi1, 1University of Jordan, Amman, Jordan, 2Mansoura University, Al Mansoura, Egypt

    Background/Purpose: To date, data on the clinical features, diagnosis and the treatment of Eosinophilic Fasciitis (EF) patients are mostly derived from individual case reports, with…
  • Abstract Number: 0459 • ACR Convergence 2024

    Tocilizumab Demonstrates Superior Inhibition of MMP-Mediated Basement Membrane Collagen Degradation Compared to Methotrexate or Placebo

    Dovile Sinkeviciute1, Sofie Falkenloeve Madsen2, Nicolas Willumsen3, Patryk Drobinski3, Morten Karsdal3 and Anne-Christine Bay-Jensen3, 1Nordic Bioscience, Herlev, Hovedstaden, Denmark, 2University of Copenhagen, Copenhagen N, Denmark, 3Nordic Bioscience, Herlev, Denmark

    Background/Purpose: Rheumatoid arthritis (RA) pathogenesis involves a range of immune cells, for instance T-cells, neutrophils and macrophages. They produce proinflammatory factors, such as proteolytic enzymes,…
  • Abstract Number: 0693 • ACR Convergence 2024

    Behind the Bronchiectasis in Systemic Sclerosis. Prevalence and Risk Factors

    Miriam Retuerto Guerrero1, Clara Moriano2, Paula Perez Garcia3, cristiana sieiro santos4 and elvira Diez álvarez3, 1Complejo Asistencial Universitario de León, Leon, Spain, 2Hospital León, LEON, Spain, 3Complejo Asistencial Universitario de Leon, Leon, 4Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain

    Background/Purpose: Bronchiectasis (BC) has been observed in association with Systemic Sclerosis (SSc). Esophageal dysmotility, immunosuppressive drugs and the direct effect of collagen deposition in the…
  • Abstract Number: 0839 • ACR Convergence 2024

    Comprehensive Single-cell Analysis Reveals Interferon Pathway Activation and Aberrant B Cell Dynamics in APS Autoimmunity

    Haoyu Pan, Xiaohan Wei, Jinyi Qian, Shuyi Yu, Zhixia Yang, Zetao Ding, Chengde Yang and Hui Shi, Department of Rheumatology and lmmunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China (People's Republic)

    Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized with the presence of pathogenic antiphospholipid antibodies (aPL) by autoreactive B cells. However, it remains…
  • Abstract Number: 0911 • ACR Convergence 2024

    Activating B Cells Facilitates the Discovery of Latent Disease-associated Variants

    David Murphy, Yao Fu, Jennifer Kelly, Richard Pelikan, Graham Wiley and Patrick Gaffney, Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Although millions of disease-associated variants have been discovered using GWAS, most of these occur in non-coding regions and their mechanistic link to disease is…
  • Abstract Number: 1002 • ACR Convergence 2024

    Depression Screening in Patients with Rheumatologic Diseases in a Large Tertiary Care Center

    Sama Hajizadeh1, Yue Yin2 and Adam Dore1, 1Allegheny Health Network, Pittsburgh, PA, 2Allegheny-Singer Research Institute, Allegheny Health Network, Pittsburgh

    Background/Purpose: Depression is common and known to be associated with poorer outcomes among patients with rheumatologic diseases, likely stemming from the chronic and sometimes debilitating…
  • Abstract Number: 1151 • ACR Convergence 2024

    Clinical Characterization and Recurrence Prediction Model for Immune-Mediated Necrotizing Myopathy

    Beibei Cui1, Hongjiang Liu2, Geng Yin3 and Qibing Xie4, 1Rheumatology and Immunology, Chengdu, China (People's Republic), 2West China Hospital, Sichuan University, Chengdu, China (People's Republic), 3Department of Rheumatology and Immunology, chengdu, China (People's Republic), 4Department of Rheumatology and Immunology, Chengdu, Sichuan, China

    Background/Purpose: The primary objective of this study was to comprehensively analyze the clinical characteristics of immune-mediated necrotizing myopathy (IMNM) and develop a reliable recurrence prediction…
  • Abstract Number: 1425 • ACR Convergence 2024

    Sjögren’s Syndrome and Interstitial Lung Disease: Experience in a Collaborative Rheumatology-Pulmonology Clinic

    Sonia Jiménez Barrios1, Sandra Garrote Corral2, Juan Rigual3, Carlos de La Puente Bujidos3, Maria Angeles Blazquez Canamero4 and Jesús Loarce3, 1Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, 2Hospital Universitario Ramón y Cajal, Madrid, Spain, 3Ramón y Cajal University Hospital, Madrid, Madrid, Spain, 4Hospital Ramon y Cajal, Madrid, Madrid, Spain

    Background/Purpose: Pulmonary lung disease represents the most prevalent extra-glandular manifestation in patients with Sjögren’s syndrome (SS). Notably, interstitial lung disease (ILD) stands out as the…
  • Abstract Number: 1617 • ACR Convergence 2024

    Persistence of Imaging Abnormality in Patients with Large Vessel Vasculitis Despite Clinical Remission

    Luigi Boiardi1, Pierluigi Macchioni1, Francesco Muratore2, Chiara Marvisi1, Caterina Ricordi1, Annibale Versari1, Giulia Besutti1, Lucia Spaggiari1, Stefania Croci1 and Carlo Salvarani1, 1Azienda Sanitaria Locale, IRCSS, Reggio Emilia, Reggio Emilia, Italy, 2Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy

    Background/Purpose: Aim of our study was to evaluate the persistence of imaging abnormalities in patients with Takayasu (TAK) and large vessel giant cell arteritis (LV-GCA)…
  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 80
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology